| Company/Division name | Ferring Pharmaceuticals |
| Type of work | Manufacturing |
| If manufacturing, is the company an OEM? | Yes |
| Reshoring category: | Transplant |
| Total number of jobs (added or to be added): | 375 |
| What product(s) and/or service(s) were outsourced domestically? | Manufacturing |
| Year reshoring announced: | 2014 |
| Year reshoring implemented or to be implemented: | 2016 |
| Offshore, work was done: | In-house |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 135 |
| $/year of sales of reshored product or service: | 200 |
| Country(ies) from which reshored: | Swaziland |
| City reshored to: | Parsippany |
| State(s) reshored to: | NJ |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | Pharmaceuticals |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Higher productivity, Manufacturing/engineering joint innovation (R&D) |
